acetohexamide
Trade name: dymelor
Approved
Dec 23, 1964
Acetohexamide (trade name Dymelor) is a first-generation sulfonylurea medication used to treat diabetes mellitus type 2, particularly in people whose diabetes cannot be controlled by diet alone. It lowers blood sugar by stimulating the pancreatic beta cells to secrete insulin and by helping the body use insulin efficiently. The pancreas must produce insulin for this medication to work. Acetohexamide binds to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing out flux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granule with the cell membrane, and therefore increased secretion of (pro) insulin. Acetohexamide extensively metabolized in the liver to the active metabolite hydroxyhexamide, which exhibits greater hypoglycemic potency than acetohexamide. Hydroxyhexamide is believed to be responsible for prolonged hypoglycemic effects. Symptoms of an acetohexamide overdose include hunger, nausea, anxiety, cold sweats, weakness, drowsiness, unconsciousness, and coma. Acetohexamide has been discontinued in the US market. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 4 marketing orgs
Timeline
1980s
- Feb 9, 1987
Ani Pharmaceuticals — Marketing Organization
- Nov 25, 1987
Teva — Marketing Organization
Indications
Approved for
Mechanism of action
Approval history
- approvedPriority reviewDec 23, 1964
Chemistry & pharmacology
SMILES
CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2- Mol. weight
- 324.395 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaAcetohexamide ↗
- NCATSQGC8W08I6I ↗
- ChEMBLCHEMBL289556 ↗
- ChEMBLCHEMBL1589 ↗
Also known as
- 1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-n-(cyclohexylcarbamoyl)benzenesulfonamide
- 1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-n-(cyclohexylcarbamoyl)benzenesulfonamide
- 1-((p-acetylphenyl)sulfonyl)-3-cyclohexylurea
- 1-((p-acetylphenyl)sulfonyl)-3-cyclohexylurea
- 33006
- 33006
- acetohexamid
- acetohexamid
- acetohexamid
- acetohexamida
- acetohexamida
- acetohexamide
- acetohexamide
- acetohexamide
- acetohexamide
- acetohexamide
- acetohexamide
- acetohexamide
- acetohexamide
- acetohexamide
- acétohexamide
- acétohexamide
- acetohexamidum
- acetohexamidum
- dimelor
- dimelor
- dymelor
- dymelor
- dymelor
- dymelor
- dymelor
- dymelor
- dymelor
- n-(p-acetylphenylsulfonyl)-n'-cyclohexylurea
- n-(p-acetylphenylsulfonyl)-n'-cyclohexylurea
Organizations
Marketing (6)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Ani Pharmaceuticals | For profit | MKTG | Feb 9, 1987 |
| Ani Pharmaceuticals | For profit | SYN | Feb 9, 1987 |
| Eli Lilly | For profit | SYN | Dec 23, 1964 |
| Eli Lilly | For profit | NDA | Dec 23, 1964 |
| Teva | For profit | MKTG | Nov 25, 1987 |
| Upsher-Smith Laboratories | For profit | MKTG | — |